WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has ...

WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the ...

The FDA approved cosibelimab (Unloxcyt) for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults who are not candidates for curative surgery or radiation.

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The ...

(RTTNews) - Checkpoint Therapeutics, Inc. (CKPT) Monday said the Food and Drug Administration (FDA) has declined to approve cosibelimab for the treatment of patients with cutaneous squamous cell ...

Patients with metastatic cutaneous squamous cell carcinoma achieved promising response rates after treatment with cosibelimab. If approved, drug developers are hoping to offer cosibelimab as a more ...

LOUISVILLE, K.Y., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for ...

The US Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor cosibelimab (Unloxcyt; Checkpoint Therapeutics, Inc.) for the treatment of adults with metastatic or locally ...

a As assessed by independent central review. “We are excited to see the substantial increases in the rate of patients experiencing a complete response of their cSCC tumors with further cosibelimab ...

WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (CKPT) (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the ...